No reduction in COVID-19 mortality risk with routine hydroxychloroquine use in RMD patients
Use of hydroxychloroquine for the treatment of rheumatic and musculoskeletal diseases is not associated with a reduction in COVID-19 mortality risk, suggest findings from an observational study published in The Lancet Rheumatology.